EMERYVILLE, Calif.--(BUSINESS WIRE)--Amyris, Inc. (NASDAQ:AMRS) announced today the pricing of its initial public offering of 5,300,000 shares of its common stock, at $16.00 per share. All shares are being sold by the company. Amyris has granted the underwriters an option to purchase up to an additional 795,000 shares at the initial public offering price to cover overallotments, if any. The common stock will trade on the NASDAQ Global Market under the symbol "AMRS."
Morgan Stanley & Co., Goldman, Sachs & Co. and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering. Itaú USA Securities Inc. and Stifel Nicolaus Weisel are acting as co-managers for the offering.
A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering of these securities will be made only by means of a prospectus, copies of which may be obtained from Morgan Stanley & Co. Incorporated, via telephone: (866) 718-1649; email: firstname.lastname@example.org; or standard mail at Morgan Stanley & Co. Incorporated, Attn: Prospectus Department, 180 Varick Street, New York, NY 10014; from Goldman, Sachs & Co., via telephone: (866) 471-2526; facsimile: (212) 902-9316; email: email@example.com; or standard mail at Goldman, Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282-2198; or from J.P. Morgan Securities LLC, via telephone: (718) 242-8002; or standard mail at c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717.
Amyris is building an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. Amyris Brasil S.A., a subsidiary of Amyris, oversees the establishment and expansion of Amyris's production in Brazil, including SMA Indústria Química S.A., its joint venture with Usina São Martinho. In addition, Amyris is building fuels distribution capabilities in the United States through its subsidiary, Amyris Fuels LLC.
Contacts Jeryl Hilleman - Amyris, Inc. Chief Financial Officer 510-740-7481 firstname.lastname@example.org or Erica Mannion - Sapphire Investor Relations Investor Relations 212-766-1800 Ext. 203 email@example.com